Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2020-07-06 Regulatory Filings
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from Vir Biotechnology, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references a registration statement filing and is a formal communication related to the securities offering process. The document is short (1842 characters) and does not contain financial statements or detailed financial data. It is not a report itself but an official regulatory filing related to the registration process. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-07-06 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) or registration of securities under the Securities Act of 1933. It includes detailed information about the company, the securities being offered, risk factors, use of proceeds, underwriting, and other disclosures typical of a registration statement. This is not a financial report, earnings release, or any other type of periodic report. It is a capital markets filing related to the company's offering of securities to the public. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Since an S-1 is a registration statement for a public offering, it fits best under Capital/Financing Update (CAP).
2020-07-06 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new director to the company's board, including background, independence determination, compensation, and indemnification agreement. This fits the category of announcements related to changes in the company's board of directors. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy statement or voting results announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2020-07-06 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-03 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-03 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.